Clinical Trial Update: MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating MK-2206 with erlotinib in advanced non-small cell lung cancer patients who progressed after prior erlotinib; the trial completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Adenosquamous Carcinoma of the Lung
• Large Cell Carcinoma of the Lung
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-10-17